Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalTSX:EDT +2.26%11 9-Day RSI is 54.46 as of Jul. 15, 2026. GuruFocus rates TSX:EDT with a GF Score™ of 11/100 and a GF Value™ of C$0.92 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 65.44% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-15), Spectral Medical's 9-Day RSI is 54.46.
The industry rank for Spectral Medical's 9-Day RSI or its related term are showing as below:
TSX:EDT's 9-Day RSI is ranked worse than 65.44% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.73
vs TSX:EDT: 54.46
Spectral Medical (TSX:EDT) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Spectral Medical 9-Day RSI Related Terms
TSX:EDT vs TMO, DHR, IDXX: 9-Day RSI Comparison
For the Diagnostics & Research subindustry, Spectral Medical's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical 9-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Spectral Medical's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (TSX:EDT) has a 9-Day RSI of 54.46 as of Jul. 15, 2026. According to the industry distribution chart, Spectral Medical ranks #142 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 65.4%.
Is Spectral Medical's 9-Day RSI too high?
Spectral Medical's current 9-Day RSI is 54.46. The Medical Diagnostics & Research industry median 9-Day RSI is 48.73. Spectral Medical's value of 54.46 is 11.8% above this industry median. Based on the distribution chart, Spectral Medical ranks #142 out of 217 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Spectral Medical has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's 9-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #142 out of 217 companies for 9-Day RSI. This places Spectral Medical in the lower half of its industry. The industry median 9-Day RSI is 48.73. Spectral Medical's value of 54.46 is 11.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Diagnostics & Research company?
The median 9-Day RSI among Medical Diagnostics & Research companies is 48.73, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current 9-Day RSI of 54.46 is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median 9-Day RSI is 48.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current 9-Day RSI is 54.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (TSX:EDT) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.92, compared to a current price of C$1.36 — trading 47.8% above its estimated fair value. The current 9-Day RSI is 54.46 and 11.8% above the Medical Diagnostics & Research industry median of 48.73. Spectral Medical's overall GF Score™ is 11/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Spectral Medical (TSX:EDT), the current 9-Day RSI is 54.46 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (TSX:EDT) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of C$1.36 is trading 47.8% above its estimated GF Value™ of C$0.92.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for TSX:EDT:
9-Day RSI: 54.46
GF Value™: C$0.92 vs. price of C$1.36 (47.8% above fair value)
Industry Position: 11.8% above the Medical Diagnostics & Research median (#142 of 217)
No single metric tells the full story. See the TSX:EDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
11GF Score
Get the complete analysis for TSX:EDT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:EDT has been successfully added to your 
